278 results on '"Hsiehchen, David"'
Search Results
2. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial
3. PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer
4. Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib
5. Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
6. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
7. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma
8. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
9. Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
10. EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma
11. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
12. Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era
13. Differences in systemic immune parameters in individuals with lung cancer according to race
14. Trends in Adjuvant Chemotherapy Use Among Stage III Colon Cancer in Non-Elderly and Low Comorbidity Patients
15. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
16. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
17. Industry Payments Are Prevalent and Contagious in Subspecialty Medical Education
18. Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding
19. Trends and clinical features of intentional and accidental adult foreign body ingestions in the United States, 2000 to 2017
20. Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing
21. pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding
22. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
23. Biomarkers for RBM39 degradation in acute myeloid leukemia
24. Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma
25. Data from Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma
26. T-cell tolerant fraction as a predictor of immune-related adverse events
27. Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net Hospital
28. Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell Carcinoma
29. Data from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
30. FIGURE 1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
31. TABLE 1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
32. Figure S1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
33. TABLE 2 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
34. FIGURE 2 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
35. Table S1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
36. Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
37. Table S1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
38. Data from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
39. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma
40. Characteristics and clinical outcomes in young‐onset cholangiocarcinoma
41. Supplementary Table S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
42. Data from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
43. Supplementary Figure S3 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
44. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
45. Evolution of collaboration and optimization of impact: self-organization in multinational research
46. Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
47. Supplementary Figure S5 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma
48. Supplementary Figure Legends from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma
49. Data from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma
50. Systematic characterization of gastrointestinal clinical trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.